IL30168A - Antigen-free vaccine and process for preparing it - Google Patents
Antigen-free vaccine and process for preparing itInfo
- Publication number
- IL30168A IL30168A IL30168A IL3016868A IL30168A IL 30168 A IL30168 A IL 30168A IL 30168 A IL30168 A IL 30168A IL 3016868 A IL3016868 A IL 3016868A IL 30168 A IL30168 A IL 30168A
- Authority
- IL
- Israel
- Prior art keywords
- vaccine
- antigen
- informationally
- active
- free
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 36
- 238000004519 manufacturing process Methods 0.000 title description 8
- 229920002477 rna polymer Polymers 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 210000004671 cell-free system Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- 229940001007 aluminium phosphate Drugs 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 5
- 241000282560 Macaca mulatta Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940109357 desoxyribonuclease Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEJ0033936 | 1967-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL30168A0 IL30168A0 (en) | 1968-08-22 |
| IL30168A true IL30168A (en) | 1973-05-31 |
Family
ID=7204943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL30168A IL30168A (en) | 1967-06-19 | 1968-06-12 | Antigen-free vaccine and process for preparing it |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE754934A (fr) * | 1969-08-16 | 1971-02-17 | Jachertz Diether | Procede de production enzymatique d'arn-messager |
| GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
| DE3115559A1 (de) * | 1981-04-16 | 1982-10-28 | Kommanditgesellschaft Schwarzhaupt, 5000 Köln | Hochgereinigte informatorische ribonukleinsaeure (i-rns), verfahren zur herstellung und verwendung derselben |
| GB2216416B (en) * | 1988-03-11 | 1992-06-24 | Sandoz Ltd | Nucleobase source for the stimulation of the immune system |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6867195B1 (en) | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
-
1967
- 1967-06-19 DE DE1617545A patent/DE1617545C2/de not_active Expired
-
1968
- 1968-06-12 IL IL30168A patent/IL30168A/en unknown
- 1968-06-15 NO NO2340/68A patent/NO124840B/no unknown
- 1968-06-17 CH CH893668A patent/CH513241A/de not_active IP Right Cessation
- 1968-06-17 IE IE713/68A patent/IE32140B1/xx unknown
- 1968-06-17 NL NL6808486A patent/NL6808486A/xx unknown
- 1968-06-17 AT AT576668A patent/AT282821B/de not_active IP Right Cessation
- 1968-06-18 DK DK286268AA patent/DK119724B/da unknown
- 1968-06-18 ES ES355121A patent/ES355121A1/es not_active Expired
- 1968-06-19 BE BE716806D patent/BE716806A/xx unknown
- 1968-06-19 FR FR1588820D patent/FR1588820A/fr not_active Expired
- 1968-06-19 GB GB1229888D patent/GB1229888A/en not_active Expired
- 1968-06-19 BR BR199970/68A patent/BR6899970D0/pt unknown
- 1968-09-18 FR FR166589A patent/FR7781M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE716806A (enrdf_load_stackoverflow) | 1968-12-19 |
| NL6808486A (enrdf_load_stackoverflow) | 1968-12-20 |
| ES355121A1 (es) | 1969-11-16 |
| DE1617545A1 (de) | 1971-04-01 |
| CH513241A (de) | 1971-09-30 |
| NO124840B (enrdf_load_stackoverflow) | 1972-06-12 |
| FR1588820A (enrdf_load_stackoverflow) | 1970-03-16 |
| DK119724B (da) | 1971-02-15 |
| IE32140L (en) | 1968-12-19 |
| AT282821B (de) | 1970-07-10 |
| FR7781M (enrdf_load_stackoverflow) | 1970-03-23 |
| IE32140B1 (en) | 1973-04-18 |
| GB1229888A (enrdf_load_stackoverflow) | 1971-04-28 |
| DE1617545C2 (de) | 1983-11-03 |
| BR6899970D0 (pt) | 1973-02-13 |
| IL30168A0 (en) | 1968-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pinto et al. | Immune response to virus-infection-associated (VIA) antigen in cattle repeatedly vaccinated with foot-and-mouth disease virus inactivated by formalin or acetylethyleneimine | |
| JPH01125328A (ja) | 髄膜炎菌ワクチン | |
| NO309675B1 (no) | Kombinert vaksine omfattende hepatitt B-overflateantigen | |
| JPS61200924A (ja) | 合成免疫原 | |
| CN106999569B (zh) | 肠道病毒灭活的改进的方法、佐剂吸附及其获得的剂量减少的疫苗组合物 | |
| Olsen et al. | Abrogation of resistance to feline oncornavirus disease by immunization with killed feline leukemia virus | |
| EP2661277A2 (en) | A combination heptavalent vaccine | |
| UA119244C2 (uk) | Бактеріальна вакцина і спосіб її одержання | |
| US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
| RU2447898C2 (ru) | Вакцина ipv-dpt | |
| IL30168A (en) | Antigen-free vaccine and process for preparing it | |
| Schmidt et al. | The complement-fixing antigen of rubella virus. | |
| US3562387A (en) | Mink virus enteritis vaccine and method for the production thereof | |
| AU774649B2 (en) | Vaccine preparations containing attenuated toxin | |
| US3318775A (en) | Production of viral antigens with n-acetyl-ethyleneimine | |
| Nair et al. | A comparative study of the immune responses of sheep against foot-and-mouth disease virus types Asia-1 and O PEG-concentrated aluminium hydroxide gel and oil-adjuvanted vaccines | |
| JPH0341034A (ja) | ネコ科動物感染性腹膜炎ワクチン | |
| RU2712750C1 (ru) | Амилоидный конъюгат, его применения и способы | |
| US7615226B2 (en) | Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant | |
| Beck | Review of studies with inactivated rubella virus | |
| George et al. | Route‐Related Variation in the Immunogenicity of Killed Salmonella enteritidis Vaccine: Role of Antigen Presenting Cells | |
| US11213579B2 (en) | Vaccines with enhanced immunogenicity, low allergenicity and reactogenicity | |
| US3097143A (en) | Myristyl-gamma-picolinium chloride preserved polio vaccine and its production | |
| RU2148412C1 (ru) | Способ получения протективного коклюшного антигена | |
| US20220313816A1 (en) | Compositions and methods for antibody-as-adjuvant vaccines and therapeutics |